Company’s 36-month beta value is -0.03.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for LYRA is 56.00M, and currently, short sellers hold a 3.82% ratio of that floaft. The average trading volume of LYRA on November 07, 2024 was 1.00M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LYRA) stock’s latest price update
Lyra Therapeutics Inc (NASDAQ: LYRA) has seen a decline in its stock price by -3.05 in relation to its previous close of 0.28. However, the company has experienced a -1.29% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-15 that — Topline Results Expected Q2 2025 — WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN 2 are expected in Q2 2025.
LYRA’s Market Performance
LYRA’s stock has fallen by -1.29% in the past week, with a monthly rise of 21.57% and a quarterly drop of -9.55%. The volatility ratio for the week is 6.69% while the volatility levels for the last 30 days are 8.51% for Lyra Therapeutics Inc The simple moving average for the last 20 days is 6.77% for LYRA stock, with a simple moving average of -86.78% for the last 200 days.
Analysts’ Opinion of LYRA
Many brokerage firms have already submitted their reports for LYRA stocks, with Jefferies repeating the rating for LYRA by listing it as a “Hold.” The predicted price for LYRA in the upcoming period, according to Jefferies is $0.50 based on the research report published on May 07, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYRA reach a price target of $2, previously predicting the price at $12. The rating they have provided for LYRA stocks is “Neutral” according to the report published on May 07th, 2024.
LYRA Trading at 4.04% from the 50-Day Moving Average
After a stumble in the market that brought LYRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.00% of loss for the given period.
Volatility was left at 8.51%, however, over the last 30 days, the volatility rate increased by 6.69%, as shares surge +23.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.97% lower at present.
During the last 5 trading sessions, LYRA fell by -0.29%, which changed the moving average for the period of 200-days by -94.02% in comparison to the 20-day moving average, which settled at $0.2543. In addition, Lyra Therapeutics Inc saw -94.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LYRA starting from Waksal Harlan, who purchase 25,000 shares at the price of $2.96 back on Nov 10 ’23. After this action, Waksal Harlan now owns 261,966 shares of Lyra Therapeutics Inc, valued at $74,095 using the latest closing price.
Stock Fundamentals for LYRA
Current profitability levels for the company are sitting at:
- -41.01 for the present operating margin
- -6.0 for the gross margin
The net margin for Lyra Therapeutics Inc stands at -55.71. The total capital return value is set at -0.99. Equity return is now at value -156.52, with -92.07 for asset returns.
Based on Lyra Therapeutics Inc (LYRA), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -2.06. The debt to equity ratio resting at 1.19. The interest coverage ratio of the stock is -69.62.
Currently, EBITDA for the company is -65.25 million with net debt to EBITDA at -0.07. When we switch over and look at the enterprise to sales, we see a ratio of 12.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.60.
Conclusion
In a nutshell, Lyra Therapeutics Inc (LYRA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
